FDA Grants Accelerated Approval for Tivdak (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

[unable to retrieve full-text content]BOTHELL, Wash. & COPENHAGEN, Denmark–(BUSINESS WIRE) September 20, 2021– Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to… Drugs.com – New Drug Approvals